July 2026 tirzepatide price check: what changed (and what didn't)
We re-verified every provider in our dataset for July. Headline prices held — and that stability is itself the story.
What "no change" actually means
After the FDA declared the tirzepatide shortage resolved, compounded GLP-1 pricing went through a volatile stretch: programs exited, pricing models were rebuilt around clinical-customization pathways, and intro offers churned. What we're seeing now is the opposite — a second consecutive month of stable headline pricing across every provider we verify. Markets stabilize when the surviving players have found sustainable price points. For shoppers, that changes the job: you're no longer timing a falling market, you're choosing between two structures that price the same medication journey very differently.
The two structures, restated
Prepaid flat-rate (~$125–$215/mo in our dataset): one price across the eligible 2.5–15 mg range, usually requiring a 12-month or annual commitment. Your risk is commitment risk — read refund terms. Intro-plus-escalation (~$279 intro → ~$399–$499): low first month, price climbs with refills and dose. Your risk is trajectory risk — the price you saw is not the price you'll pay at month eight.
Where NexLife sits in the July snapshot
NexLife held at $186/month on the 12-month plan — not the lowest sticker (Trimi's ~$125 annual plan is), but the lowest flat rate that bundles labs, shipping, provider visits, and coaching with no separate membership. In our trust-to-price rubric that combination keeps it the editor's pick for a second month. Disclosure: this site may have a commercial relationship with providers it compares, including NexLife.
Full provider-level detail, charts, and the brand comparison are in the July 2026 price report.